QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.106013v1 318/3/1220    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Galetin, A. Articles by Houston, J. B. Search for Related Content PubMed PubMed Citation Articles by Galetin, A. Articles by Houston, J. B. Pubmed/NCBI databases Substance via MeSH

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

The contribution of the gut is not routinely incorporated into in vitro-in vivo predictions of either clearance or drug-drug interactions, and this omission may partially explain the general underprediction trend often observed. In the current study, the metabolic ability of hepatic and intestinal pooled microsomes was compared for eight CYP3A substrates (midazolam, triazolam, diazepam, alprazolam, flunitrazepam, nifedipine, testosterone, and quinidine) and paclitaxel, tolbutamide, S-mephenytoin, and bufuralol as CYP2C8, CYP2C9, CYP2C19, and CYP2D6 probes, respectively. A general agreement in the type of kinetics was observed between the two systems for the substrates investigated. Of the 16 pathways investigated, 75% of K_m (S₅₀) values obtained in intestinal microsomes (5.9-769 µM) were within 2-fold of hepatic estimates. Irrespective of the cytochrome P450 (P450) investigated and normalization of V_max values for the P450 abundance, clearance was 4.5- to 50-fold lower in intestinal microsomes (0.0005-0.51 µl/min/P450) compared with the hepatic estimates (0.002-5.8 µl/min/P450), whereas the rank order was consistent between the systems. Assessment of two enterocyte isolation methods (mucosal scraping or enterocyte elution) was performed at the substrate concentrations corresponding to the determined V_max conditions for 11 pathways. The activity difference between the methods (3-29-fold) was P450-related in the following rank order: CYP2C19 > CYP3A4 > CYP2C9 CYP2D6. After correction for the loss of activity between the methods, the intrinsic activities of hepatic and intestinal CYP3A4, CYP2C9, CYP2C19, and CYP2D6 were comparable for the 16 pathways. The implications of these findings on the prediction of intestinal first-pass metabolism are discussed.

Address correspondence to: Dr. Aleksandra Galetin, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK. E-mail: Aleksandra.Galetin{at}manchester.ac.uk

This article has been cited by other articles:

				X. Zhang, S. K. Quinney, J. C. Gorski, D. R. Jones, and S. D. Hall Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite Drug Metab. Dispos., August 1, 2009; 37(8): 1587 - 1597. [Abstract] [Full Text] [PDF]

				S.-Y. Chang, C. Chen, Z. Yang, and A. D. Rodrigues Further Assessment of 17{alpha}-Ethinyl Estradiol as an Inhibitor of Different Human Cytochrome P450 Forms in Vitro Drug Metab. Dispos., August 1, 2009; 37(8): 1667 - 1675. [Abstract] [Full Text] [PDF]

				J. Henshall, A. Galetin, A. Harrison, and J. B. Houston Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications Drug Metab. Dispos., July 1, 2008; 36(7): 1332 - 1340. [Abstract] [Full Text] [PDF]

				S. Lofgren, R. M. Baldwin, M. Hiratsuka, A. Lindqvist, A. Carlberg, S. C. Sim, M. Schulke, M. Snait, A. Edenro, R. Fransson-Steen, et al. Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression Drug Metab. Dispos., May 1, 2008; 36(5): 955 - 962. [Abstract] [Full Text] [PDF]

				Y. Shirasaka, Y. Masaoka, M. Kataoka, S. Sakuma, and S. Yamashita Scaling of in Vitro Membrane Permeability to Predict P-glycoprotein-Mediated Drug Absorption in Vivo Drug Metab. Dispos., May 1, 2008; 36(5): 916 - 922. [Abstract] [Full Text] [PDF]

				M. Gertz, P. J. Kilford, J. B. Houston, and A. Galetin Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations Drug Metab. Dispos., March 1, 2008; 36(3): 535 - 542. [Abstract] [Full Text] [PDF]

				P. A. Gurbel, W. C. Lau, and U. S. Tantry Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel J. Am. Coll. Cardiol., January 22, 2008; 51(3): 261 - 263. [Full Text] [PDF]

				A. Di Marco, A. Cellucci, A. Chaudhary, M. Fonsi, and R. Laufer High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin Drug Metab. Dispos., October 1, 2007; 35(10): 1737 - 1743. [Abstract] [Full Text] [PDF]